title: Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.
abstract: OBJECTIVE
  To compare the occurrence of normal visual field (VF) test results following 2 vs 3 consecutive, abnormal, reliable test results in the Ocular Hypertension Treatment Study.
  
  
  METHODS
  The Ocular Hypertension Treatment Study is a prospective, multicenter follow-up study as part of a longitudinal randomized clinical trial. Sixty-four (68 eyes) of 1636 participants developed a VF primary open-angle glaucoma (POAG) end point. We compared the proportion of normal VF test results after a VF POAG end point among eyes whose VF abnormality was confirmed by 2 (n = 9 eyes) vs 3 (n = 59 eyes) consecutive, abnormal, reliable VF test results.
  
  
  RESULTS
  The proportion of VF test results that were normal subsequent to a VF POAG end point in eyes whose abnormality was confirmed by 2 consecutive, abnormal, reliable test results was significantly higher (73 [66%] of 110) compared with eyes whose abnormality was confirmed by 3 consecutive, abnormal, reliable test results (46 [12%] of 381) (P = .01).
  
  
  CONCLUSIONS
  A VF POAG end point confirmed by 3 consecutive, abnormal, reliable VF test results appears to have greater specificity and stability than either 1 or 2 consecutive, abnormal, reliable VF test results. However, some eyes whose VF POAG end point was confirmed by 3 consecutive, abnormal, reliable test results nonetheless had 1 or more normal test results on follow-up.
authors.affiliation: Visual Field Reading Center, Department of Ophthalmology, University of California-Davis, 4860 "Y" Street, Ste. 2400, Sacramento, CA 95817, USA. jlkeltner@ucdavis.edu
authors.forename: John L
authors.initials: JL
authors.lastname: Keltner
authors.forename: Chris A
authors.initials: CA
authors.lastname: Johnson
authors.forename: Richard A
authors.initials: RA
authors.lastname: Levine
authors.forename: Juanjuan
authors.initials: J
authors.lastname: Fan
authors.forename: Kimberly E
authors.initials: KE
authors.lastname: Cello
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000188:drug therapy; D011446:Prospective Studies; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014786:Vision Disorders / Q000175:diagnosis*; D058609:Visual Field Tests / Q000379:methods; D014794:Visual Fields
chemical_list: D000959:Antihypertensive Agents